Viridian Therapeutics, Inc./DE
Balance Sheet
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||
| Cash & Equivalents | $212.4M | $99.6M | $102.8M | $155.6M | $42.3M | $45.9M | $24.8M | $32.6M |
| Accounts Receivable | — | — | — | — | — | — | $108.0K | $24.0K |
| Inventory | — | — | — | — | — | — | — | — |
| Total Current Assets | $894.2M | $738.5M | $486.5M | $431.2M | $200.2M | $129.6M | $29.7M | $65.4M |
| Property, Plant & Equipment | $1.2M | $1.2M | $1.7M | $1.3M | $375.0K | $309.0K | $523.0K | $727.0K |
| Goodwill | — | — | — | — | — | — | — | — |
| Intangible Assets (Excl. Goodwill) | — | — | — | — | — | — | — | — |
| Total Assets | $899.4M | $742.4M | $490.4M | $435.1M | $203.7M | $131.3M | $30.3M | $66.1M |
| Liabilities | ||||||||
| Accounts Payable | $8.7M | $2.1M | $2.2M | $14.2M | $2.3M | $670.0K | $1.1M | $571.0K |
| Total Current Liabilities | $70.7M | $47.9M | $26.6M | $33.3M | $13.6M | $10.7M | $10.2M | $6.7M |
| Long-Term Debt | — | $20.6M | $20.2M | $4.6M | $0 | — | $7.7M | $10.0M |
| Total Liabilities | $177.3M | $70.8M | $48.4M | $40.0M | $16.0M | $11.2M | $14.5M | $14.8M |
| Stockholders' Equity | ||||||||
| Retained Earnings | $-1.34B | $-995.9M | $-725.9M | $-488.2M | $-358.3M | $-278.9M | $-168.2M | $-126.3M |
| Total Stockholders' Equity | $722.2M | $671.6M | $442.0M | $395.1M | $187.7M | $120.0M | $15.8M | $51.3M |